Trial Profile
Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 03 Sep 2023 Status changed from recruiting to completed.
- 14 Jul 2020 Status changed from not yet recruiting to recruiting.
- 21 Jan 2020 Planned initiation date changed from 1 Dec 2019 to 1 Mar 2020.